Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F16%3A10327552" target="_blank" >RIV/00669806:_____/16:10327552 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11140/16:10327552

Result on the web

<a href="http://www.sciencedirect.com/science/article/pii/S1590865815302334" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1590865815302334</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.dld.2015.12.013" target="_blank" >10.1016/j.dld.2015.12.013</a>

Result language

angličtina

Original language name

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

Original language description

BACKGROUND: Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse. AIM: To evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome. METHODS: This was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome symptoms. The primary PRO measure was satisfaction with diarrhoea control. Secondary PRO measures included severity, change in symptoms and impact on daily life of diarrhoea; and patient satisfaction with flushing control. RESULTS: Of 273 patients enrolled, 76% were 'completely' or 'rather' satisfied with diarrhoea control; 79% reported improvement in diarrhoea with lanreotide. The proportion of patients with 'mild', 'minimal', or 'no diarrhoea' increased from 33% before treatment to 75% during treatment; 75% were unconcerned about the impact of diarrhoea on daily life. Satisfaction with flushing control amongst patients with significant flushing at treatment initiation was 73%. CONCLUSIONS: Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Digestive and Liver Disease

ISSN

1590-8658

e-ISSN

—

Volume of the periodical

48

Issue of the periodical within the volume

5

Country of publishing house

IT - ITALY

Number of pages

7

Pages from-to

552-558

UT code for WoS article

000373721200014

EID of the result in the Scopus database

2-s2.0-84963541109